Associations - HER-2 negative

HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline Clin Breast Cancer - 1 week
HER-2 negative HER-2 negative	Gastric Cancer Gastric Cancer	cisplatin + capecitabine Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	cisplatin + capecitabine Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CaT Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	CAPOX Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	FP Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Gastric Cancer Gastric Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Gastric Cancer Gastric Cancer	CAPOX Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Gastric Cancer Gastric Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	docetaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	bevacizumab Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ixabepilone Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + docetaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	tamoxifen Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	TC Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant + anastrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant + letrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	abemaciclib Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	exemestane Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	EC Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CMF Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	AC Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	TAC Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GT Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	epirubicin Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	cyclophosphamide oral Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	lyso-thermosensitive liposomal doxorubicin Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Esophageal Cancer Esophageal Cancer	XP Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Esophageal Cancer Esophageal Cancer	FP Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	Esophageal Cancer Esophageal Cancer	capecitabine + oxaliplatin Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	POL 6326 Sensitive: B - Late Trials
HER-2 negative HER-2 negative	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: B - Late Trials
HER-2 negative HER-2 negative	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	ramucirumab Sensitive: B - Late Trials
HER-2 negative HER-2 negative	Gastric Cancer Gastric Cancer	ramucirumab Sensitive: B - Late Trials
HER-2 negative HER-2 negative	Gastric Cancer Gastric Cancer	nivolumab Sensitive: B - Late Trials
HER-2 negative HER-2 negative	Breast Cancer Breast Cancer	abemaciclib Sensitive: B - Late Trials
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	E7389-LF Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	rivoceranib Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	Gastric Cancer Gastric Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	capecitabine + vinorelbine tartrate Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	lapatinib Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	cabazitaxel Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	anlotinib Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	camrelizumab Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	Gastric Cancer Gastric Cancer	camrelizumab Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	rivoceranib + camrelizumab Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	Gastric Cancer Gastric Cancer	rivoceranib + camrelizumab Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	MLN8237 Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GC Sensitive: C3 – Early Trials
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	NLG8189 Resistant: C3 – Early Trials
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	bevacizumab + ME-344 Sensitive: C3 – Early Trials
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	APG-1387 Sensitive: C3 – Early Trials
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	docetaxel + doxorubicin hydrochloride Resistant: C4 – Case Studies
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK6 inhibitor + CDK4 inhibitor Sensitive: C4 – Case Studies
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	trastuzumab Resistant: D – Preclinical
HER-2 negative HER-2 negative	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ZEN-3694 Sensitive: D – Preclinical
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	etoposide IV Sensitive: D – Preclinical